 |
- Acquisition positions Servier as a pacesetter in pediatric low-grade glioma and expands its pipeline with applications focusing on grownup and pediatric cancers with excessive unmet wants.
- Transaction represents complete fairness worth of roughly $2.5 billion.
SURESNES, France and BRISBANE, Calif., March 7, 2026 /PRNewswire/ — Servier, an impartial worldwide pharmaceutical group ruled by a basis, and Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical firm devoted to creating and commercializing focused therapies for individuals of all ages with life-threatening ailments, as we speak introduced that they’ve entered right into a definitive settlement for Servier to amass Day One for $21.50 per share in money, representing a complete fairness worth of roughly $2.5 billion. The transaction stays topic to customary closing situations and is predicted to shut within the second quarter of 2026.
This acquisition will reinforce Servier’s place in oncology focused therapies in step with its 2030 ambition to develop revolutionary therapies for sufferers with excessive unmet medical wants. It strengthens Servier’s portfolio and expands its oncology pipeline with applications starting from early stage to section 3. The mix of Day One’s scientific experience with Servier’s established international capabilities advances a shared dedication to delivering revolutionary options for sufferers worldwide.
“This acquisition of Day One Biopharmaceuticals marks one other decisive step in strengthening Servier’s place in uncommon oncology,” stated Olivier Laureau, President of Servier. “It displays our long-term dedication to investing in science that may make a significant distinction for sufferers. This announcement is totally aligned with our 2030 ambition, and we consider that combining our experience will speed up innovation for individuals dwelling with a uncommon most cancers.”
“Servier’s profitable observe file in uncommon cancers and its dedication to advancing focused therapies makes it the perfect house for our portfolio as a part of Day One’s mission to carry medicines to sufferers of all ages with life threatening ailments” stated Jeremy Bender, Ph.D., chief government officer of Day One. “Becoming a member of Servier represents a novel alternative to increase the attain of our science and our lead program in pediatric low–grade glioma. Importantly, Servier’s dedication to the uncommon illness neighborhood preserves the affected person–first mindset that has outlined our firm for the reason that starting and has pushed our deep dedication to the communities we serve.”
Contacts
Servier Group
Laura Visserias
laura.visserias.half@servier.com
Day One Biopharmaceuticals
Media
media@dayonebio.com
PDF – https://mma.prnewswire.com/media/2928148/Servier_DayOne.pdf
